Report Detail

Medical Devices & Consumables Endologix Inc (ELGX) - Financial and Strategic SWOT Analysis Review

  • RnM1866125
  • |
  • 11 June, 2019
  • |
  • Global
  • |
  • 46 Pages
  • |
  • GlobalData
  • |
  • Medical Devices & Consumables

Endologix Inc (ELGX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Endologix, Inc. (Endologix) is a medical device company. It undertakes the development, manufacturing and selling of minimally invasive devices in treatment of aortic diseases. The company lays focus on its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). The company’s AAA products are built on traditional minimally-invasive endovascular repair (EVAR) platform or endovascular sealing (EVAS) platform and Ovation system. The company’s EVAR products include AFX endovascular AAA system. Its Ovation system consists of a low-permeability polytetrafluoroethylene and a radiopaque nitinol suprarenal stent with integral anchors.

Endologix Inc Key Recent Developments

May 02,2019: Endologix reports first quarter 2019 financial results
Feb 25,2019: Endologix announces fourth quarter and fiscal year 2018 financial results
Jan 10,2019: Endologix names John D. Zehren as Chief Commercial Officer
Jan 07,2019: Endologix Announces Fourth Quarter and Full-Year 2018 Preliminary Financial Results and Provides 2019 Financial Guidance
Nov 15,2018: Endologix honors innovators of aortic therapy at VEITHsymposium

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Table of Contents

    Table of Contents

      List of Tables

        List of Figures

          Section 1 - About the Company

            Endologix Inc - Key Facts

              Endologix Inc - Key Employees

                Endologix Inc - Key Employee Biographies

                  Endologix Inc - Major Products and Services

                    Endologix Inc - History

                      Endologix Inc - Company Statement

                        Endologix Inc - Locations And Subsidiaries

                          Head Office

                            Other Locations & Subsidiaries

                              Section 2 – Company Analysis

                                Company Overview

                                  Endologix Inc - Business Description

                                    R&D Overview

                                      Endologix Inc - Corporate Strategy

                                        Endologix Inc - SWOT Analysis

                                          SWOT Analysis - Overview

                                            Endologix Inc - Strengths

                                              Endologix Inc - Weaknesses

                                                Endologix Inc - Opportunities

                                                  Endologix Inc - Threats

                                                    Endologix Inc - Key Competitors

                                                      Section 3 – Company Financial Ratios

                                                        Financial Ratios - Capital Market Ratios

                                                          Financial Ratios - Annual Ratios

                                                            Performance Chart

                                                              Financial Performance

                                                                Financial Ratios - Interim Ratios

                                                                  Financial Ratios - Ratio Charts

                                                                    Section 4 – Company’s Lifesciences Financial Deals and Alliances

                                                                      Endologix Inc, Medical Equipment, Deals By Year, 2013 to YTD 2019

                                                                        Endologix Inc, Medical Equipment, Deals By Type, 2013 to YTD 2019

                                                                          Endologix Inc, Recent Deals Summary

                                                                            Section 5 – Company’s Recent Developments

                                                                              May 02, 2019: Endologix reports first quarter 2019 financial results

                                                                                Feb 25, 2019: Endologix announces fourth quarter and fiscal year 2018 financial results

                                                                                  Jan 10, 2019: Endologix names John D. Zehren as Chief Commercial Officer

                                                                                    Jan 07, 2019: Endologix Announces Fourth Quarter and Full-Year 2018 Preliminary Financial Results and Provides 2019 Financial Guidance

                                                                                      Nov 15, 2018: Endologix honors innovators of aortic therapy at VEITHsymposium

                                                                                        Nov 01, 2018: Endologix reports third quarter 2018 financial results

                                                                                          Oct 02, 2018: Endologix Announces Third Quarter Preliminary Revenue Results and Raises Low End of 2018 Revenue Guidance Range

                                                                                            Aug 15, 2018: Endologix appoints Jeffrey S. Brown as Chief Operations Officer

                                                                                              Aug 09, 2018: Endologix reports second quarter 2018 financial results

                                                                                                Jun 25, 2018: Endologix Names Jeffry Fecho As Chief Quality Officer

                                                                                                  Section 6 – Appendix

                                                                                                    Methodology

                                                                                                      Ratio Definitions

                                                                                                        About GlobalData

                                                                                                          Contact Us

                                                                                                            Disclaimer


                                                                                                            REPORT YOU MIGHT BE INTERESTED

                                                                                                            Purchase this Report

                                                                                                            $500.00
                                                                                                            $1,000.00
                                                                                                            $1,500.00
                                                                                                            399.50
                                                                                                            799.00
                                                                                                            1,198.50
                                                                                                            464.50
                                                                                                            929.00
                                                                                                            1,393.50
                                                                                                            77,745.00
                                                                                                            155,490.00
                                                                                                            233,235.00
                                                                                                            41,740.00
                                                                                                            83,480.00
                                                                                                            125,220.00
                                                                                                            Credit card Logo

                                                                                                            Related Reports


                                                                                                            Reason to Buy

                                                                                                            Request for Sample of this report